Literature DB >> 32481363

Clinical implications of thoracic duct dilatation in patients with chronic liver disease.

Seung Woon Park1, Tae Hyung Kim1, Soo-Youn Ham2, Soon Ho Um1, Hyun Gil Goh1, SunHye Lee2, Han Ah Lee1, Sun Young Yim1, Yeon Seok Seo1, Hyung Joon Yim1, Hyunggin An3, Yu-Whan Oh4.   

Abstract

This study aimed to investigate the association between the degree of thoracic duct dilatation and the progression of chronic liver disease.In this cross-sectional and retrospective study, 179 patients (mean age, 60.9 years; 114 men) with chronic liver disease who underwent chest CT were enrolled. Dilatation of the left distal thoracic ducts (DTD) was measured and divided into the following 3 grades according to the maximum transverse diameter: grade 0, invisible thoracic duct; grade 1, visible duct with <5-mm diameter; grade 2, diameter of ≥5 mm. Statistical analyses were conducted using the binary logistic regression model.The proportion of grade 2 DTD was notably higher as the chronic liver disease progressed to cirrhosis. Visible DTD on chest CT was significantly related to the presence of cirrhosis (odds ratio [OR], 3.809; P = .027) and significant varix (OR, 3.211; P = .025). Grade 2 DTD was observed more frequently in patients with ascites (OR, 2.788; P = .039). However, 40% of patients with cirrhosis and ascites still exhibited no visible DTD while demonstrating significant amount of ascites, and their ascites were more predominant of recent onset and transient than that observed in other patients (85.7% vs 48.4%, P = .010 and 66.7% vs 29.0%, P = .009, respectively).The degree of thoracic duct dilatation is significantly associated with progression to cirrhosis and advancement of portal hypertension. Further, insufficient lymph drainage to DTD might contribute to the development of ascites.

Entities:  

Mesh:

Year:  2020        PMID: 32481363     DOI: 10.1097/MD.0000000000019889

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  1 in total

1.  Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites.

Authors:  Masashi Hirooka; Yohei Koizumi; Ryo Yano; Yoshiko Nakamura; Koutarou Sunago; Atsushi Yukimoto; Takao Watanabe; Osamu Yoshida; Yoshio Tokumoto; Masanori Abe; Yoichi Hiasa
Journal:  Sci Rep       Date:  2022-05-17       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.